Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

BACKGROUND Niacin as an adjunct to statin treatment to reduce cardiovascular risk is questioned. OBJECTIVE To evaluate interrelationships between the effects of niacin on mixed dyslipidemia and a spectrum of metabolic and inflammatory biomarkers. METHODS Obese, nondiabetic, hypertriglyceridemic males (n = 19) with low high-density lipoprotein… CONTINUE READING